Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12647

    +

    P3.10-055 - Long progressive free survival to paclitaxel and cisplatin in first line is associated with better response and progression free survival to docetaxel in second line in advanced non-small cell lung cancer (ID 3458)

    09:30 - 09:30  |  Author(s): D. Orta
    • Abstract

    Background
    Lung cancer is the leading cause of cancer death worldwide. Approximately 85% are of the non–small-cell lung cancers (NSCLC) histology and the majority have locally advanced or metastatic stage IV disease at diagnosis (85%). Cisplatin-based combination chemotherapy (CT) is the standard treatment in first line. Cisplatin plus paclitaxel (PT) it´s one of the most used combinations. Docetaxel (D) is approved for FDA in second line in NSCLC based in 3 phase III trials. Patients with breast cancer treated with paclitaxel (T) can respond to D. However, there is little information on lung cancer. We evaluate factors associated with response to D in patients previously treated with PT.

    Methods
    We analized consecutive patients treated in the thoracic tumors clinic of the Instituto Nacional de Cancerologia in Mexico between January 2007-december 2012 with NSCLC IV stage that previously were treated with PT and that at progression received D as second line (75mg/m2 each 3 weeks). We define as period free of Paclitaxel (PFT) the interval between the last cycle of PT and the progression of the disease, progression free survival (PFS) as interval since first cycle of CT and progression disease, and overall survival (OS) as the period from the diagnosis and death from any cause. The rate response (RR) was evaluated with RECIST criteria.

    Results
    Fifty-five patients were eligible for entry onto the study. Median age was 57.6 years (±15.1), female 54.5%, ECOG 0-1 (89.1%), cigarettes-smoking 45.5%, never smokers 54.5%; adenocarcinoma histology 74.5% and epidermoid 25.5%. The PFS to first-line was 6.7 months (IC 95% 5.8-7.6) and PFS to D was 4.3 months (IC 95% 2.8-5.9 months). The median period between last cycle of CT and progression disease was 2.99 months (IC 95% 2.1-3.9 months). The RR to D was 21.8% in all population. In patients with PFT >3 months compared with PFS <3months, the RR and PFS were 29% vs 14.3% (p 0.186) and 2.7 vs 6.7 months (p 0.021), respectively. We not found differences for type of response to first line CT neither histology subtype. The patients with partial response to D had were PFS prolonged in relation to patients with stable disease (5.3 versus 2.6 months, p 0.069).

    Conclusion
    Prior used of T not excluded for used D. Our results demonstrate that the PFT is the best predictive factor for response to D. Patients with PFT >3 months and response to D have better prognostic in relation with PFT <3months and with stable disease to D. This results must be validated in others prospective studies and Phase III trials that compared docetaxel with others therapies.